



FILE COPY

August 13, 2002

Ms. Michelle R. Flicker
Merck Research Laboratories
P. O. Box 2000
Rahway, New Jersey 07065-0900

Dear Ms. Flicker:

Your petition requesting the Food and Drug Administration to reflect the current position regarding the safety of the study of alendronate sodium tablets (Fosamax) in the pediatric population, was received by this office on 08/13/02. It was assigned docket number 02P-0363/CP 1 and it was filed on 08/13/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Dockets Management Branch

02P-0363

ACK 1